C. G. Bhakta Institute of Biotechnology

C. G. Bhakta Institute of Biotechnology is a other institution in Surat, established in 2005. C. G. Bhakta Institute of Biotechnology (CGBIT) is a private, autonomous institution established in 1998 in Surat, Gujarat, pioneering biotechnology education in Western India. Named after the visionary industrialist C.G. Bhakta, the institute was founded with a mission to create specialized professionals in biotechnology, biomedical sciences, and allied fields. Over 25 years, CGBIT has grown from a nascent institute to a recognized center of biotechnology excellence, particularly known for its industry-aligned curriculum and strong placement record in pharmaceutical, biotech, and healthcare sectors. The institute is recognized by UGC and accredited by NAAC with a Grade B+ (as of 2022). Located in Athwalines, a developing suburban pocket of Surat, CGBIT occupies a sprawling 8.5-acre campus designed with dedicated spaces for academics, research, and student life. The institute operates under a trimester system, allowing flexibility in curriculum delivery and frequent assessments. CGBIT's academic programs span undergraduate and postgraduate degrees in Biotechnology, Biomedical Engineering, Bioinformatics, Microbiology, and related disciplines. The institute maintains partnerships with leading pharmaceutical companies (Cipla, Dr. Reddy's, Torrent Pharmaceuticals) and biotech firms, facilitating internships, guest lectures, and live projects. Faculty comprise Ph.D. holders and industry professionals; approximately 70% hold Ph.D. qualifications. Research centers focus on fermentation technology, vaccines, diagnostics, and medicinal plant biotechnology, though funding and publication volume remain modest compared to IITs. The institute has produced over 2,500 alumni, predominantly employed in pharmaceutical R&D, quality assurance, and regulatory affairs roles. Placement statistics for 2023-24 show 92% overall placement with median salaries around ₹4.5-5.2 lakh for biotechnology graduates and ₹5.8-6.5 lakh for biomedical engineering graduates. Notable recruiters include Serum Institute, Cipla, Dr. Reddy's, Glenmark, Lupin, Novartis, Roche, and biotech startups in Bangalore's corridor. Campus life includes active biotechnology clubs, annual technical fest 'BioTech Summit', sports facilities, and a functioning hostel system. However, students frequently cite limited diversity in career opportunities (heavily skewed toward pharma/biotech), dated infrastructure in some labs, irregular Wi-Fi connectivity, and limited cultural diversity in student clubs. The institute is not a tier-1 brand and struggles with recognition outside biotech circles. Surat's growing pharma hub status makes CGBIT attractive for biotechnology careers; however, students seeking diverse career paths (finance, consulting, tech) or those valuing campus prestige should consider alternatives. CGBIT is best suited for students genuinely interested in biotechnology, pharmaceutical sciences, or biomedical engineering—not for those treating it as a fallback engineering option. The institute's strength lies in specialized, industry-relevant biotechnology education, not in broad engineering or general academics. Cost-effectiveness compared to other private biotech institutes and strong pharma sector placement make it a reasonable choice for biotechnology aspirants with moderate financial means.